Moody Lynn & Lieberson LLC trimmed its position in Novartis AG (NYSE:NVS – Free Report) by 8.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,289 shares of the company’s stock after selling 200 shares during the quarter. Moody Lynn & Lieberson LLC’s holdings in Novartis were worth $263,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Private Ocean LLC acquired a new position in Novartis in the 1st quarter valued at about $25,000. New Millennium Group LLC acquired a new position in shares of Novartis in the 2nd quarter worth approximately $28,000. Clearstead Trust LLC lifted its holdings in shares of Novartis by 73.5% in the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after acquiring an additional 114 shares during the last quarter. Lynx Investment Advisory acquired a new position in shares of Novartis in the 2nd quarter worth approximately $29,000. Finally, Industrial Alliance Investment Management Inc. acquired a new position in shares of Novartis in the 2nd quarter worth approximately $30,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.
Novartis Price Performance
Novartis stock opened at $113.80 on Friday. The firm has a market cap of $232.61 billion, a PE ratio of 15.36, a price-to-earnings-growth ratio of 1.66 and a beta of 0.57. Novartis AG has a 52-week low of $92.19 and a 52-week high of $120.92. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47. The company’s 50 day moving average is $116.44 and its two-hundred day moving average is $108.42.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on Novartis
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Articles
- Five stocks we like better than Novartis
- What is a Low P/E Ratio and What Does it Tell Investors?
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Buy Cheap Stocks Step by Step
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Stock Market Index and How Do You Use Them?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.